TY - JOUR
T1 - Dioon rzedowskii
T2 - An antioxidant, antibacterial and anticancer plant extract with multi-faceted effects on cell growth and molecular signaling
AU - Negm, Walaa A.
AU - Elekhnawy, Engy
AU - Mahgoub, Sebaey
AU - Ibrahim, Hanaa A.
AU - Ibrahim Elberri, Aya
AU - Abo Mansour, Hend E.
AU - Mosalam, Esraa M.
AU - Moglad, Ehssan
AU - Alzahraa Mokhtar, Fatma
N1 - Publisher Copyright:
© 2024
PY - 2024/5/10
Y1 - 2024/5/10
N2 - This study investigated the antioxidant, anticancer, antibacterial properties of Dioon rzedowskii extract, which had not been previously explored. We aimed to determine the extract's effect on liver and breast cancer cell lines and on solid Ehrlich carcinoma (SEC) mouse model to investigate the underlying molecular mechanisms. Three female albino mice groups were established: a tumor control group, a group treated with 100 mg/kg of the extract (D100), and a group treated with 200 mg/kg of the extract (D200) for 16 days after tumor development. Results showed that the D. rzedowskii extract inhibited cell growth in both MCF-7 and HepG2 cells in a concentration-dependent manner. This was achieved by suppressing the cell proliferation and inducing apoptosis. The extract also improved liver, heart, and kidney functions compared to the tumor control. Furthermore, oral administration of the extract reduced tumor volume and alleviated oxidative stress in tumor tissue. The anticancer effects were associated with overexpression of p53 and Bax and downregulation of cyclin D1 expression, which was attributed to decreased phosphorylated MAPK kinases. Additionally, D. rzedowskii exhibited antibacterial activity against K. pneumoniae isolated from cancer patients. The extract inhibited bacterial growth and reduced the membrane integrity. The study suggests that D. rzedowskii has promising potential as an adjunctive therapy for cancer treatment. Further investigations are needed to explore its combined anticancer efficacy. These results emphasize the value of natural products in developing compounds with potential anticancer activity and support a paradigm shift in cancer management to improve patients' quality of life.
AB - This study investigated the antioxidant, anticancer, antibacterial properties of Dioon rzedowskii extract, which had not been previously explored. We aimed to determine the extract's effect on liver and breast cancer cell lines and on solid Ehrlich carcinoma (SEC) mouse model to investigate the underlying molecular mechanisms. Three female albino mice groups were established: a tumor control group, a group treated with 100 mg/kg of the extract (D100), and a group treated with 200 mg/kg of the extract (D200) for 16 days after tumor development. Results showed that the D. rzedowskii extract inhibited cell growth in both MCF-7 and HepG2 cells in a concentration-dependent manner. This was achieved by suppressing the cell proliferation and inducing apoptosis. The extract also improved liver, heart, and kidney functions compared to the tumor control. Furthermore, oral administration of the extract reduced tumor volume and alleviated oxidative stress in tumor tissue. The anticancer effects were associated with overexpression of p53 and Bax and downregulation of cyclin D1 expression, which was attributed to decreased phosphorylated MAPK kinases. Additionally, D. rzedowskii exhibited antibacterial activity against K. pneumoniae isolated from cancer patients. The extract inhibited bacterial growth and reduced the membrane integrity. The study suggests that D. rzedowskii has promising potential as an adjunctive therapy for cancer treatment. Further investigations are needed to explore its combined anticancer efficacy. These results emphasize the value of natural products in developing compounds with potential anticancer activity and support a paradigm shift in cancer management to improve patients' quality of life.
KW - Antibacterial activity
KW - Dioon rzedowskii
KW - MAPK pathway
KW - Solid Ehrlich carcinoma
KW - Toxicity profile
UR - http://www.scopus.com/inward/record.url?scp=85189077106&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2024.111957
DO - 10.1016/j.intimp.2024.111957
M3 - Article
C2 - 38554441
AN - SCOPUS:85189077106
SN - 1567-5769
VL - 132
JO - International Immunopharmacology
JF - International Immunopharmacology
M1 - 111957
ER -